US EditionCuratis, Neupharma Sign Development Agreement for Corticorelin in Japan
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Curatis and Neupharma sign development agreement for corticorelin in Japan
Curatis has signed an exclusive licensing and development agreement with Neupharma for corticorelin to treat peritumoral brain oedema in Japan.The post Curatis and Neupharma sign development agreement for corticorelin in Japan appeared first on Hospital Management.
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan
Japan is one of the world's most important pharmaceutical markets after the US and Europe. Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well as speciality care medicines in Japan, including a blockbuster drug. The agreement with Neupharma includes upfront and milestone payments of up to CHF 83.5 million as [...] The post Curatis and Neupharma Announce Exclusive Licensing Agreement to De…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
